Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03390595Phase 2Completed

Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma

Role: lead

NCT03745911Phase 2Unknown

Paclitaxel and TAK-228 in Urothelial Carcinoma

Role: lead

NCT01784978Phase 2Terminated

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

Role: lead

NCT01577784Phase 2Unknown

Pazopanib in Second-line Therapy in Renal Cell Carcinoma

Role: lead

NCT01830231Phase 2Unknown

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

Role: lead

All 5 trials loaded